文献速递静脉血栓栓塞慢性静脉疾病

静脉活性药物在血栓后综合征中的应用价值:一项系统综述

Utility of venoactive compounds in post-thrombotic syndrome: A systematic review.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2025-03-16

该系统综述检索1980年1月1日至2023年7月14日文献,纳入11项随机对照试验,评估地奥司明、地奥司明/芦丁苷、微粒化纯化黄酮类组分(MPFF)和舒洛地特等静脉活性药物预防和治疗血栓后综合征的证据质量。结果显示静脉活性药物改善静脉症状、减轻水肿和促进静脉性溃疡愈合至少有中等质量证据,两项试点随机对照试验提示地奥司明和MPFF作为利伐沙班辅助治疗可降低血栓后综合征发生率并改善深静脉再通。

要点

  • 静脉活性药物改善血栓后综合征静脉症状、减轻水肿和促进溃疡愈合至少有中等质量证据。
  • 两项试点随机对照试验提示地奥司明和MPFF辅助利伐沙班可降低血栓后综合征发生率。
  • 多数随机对照试验发表于二十多年前且部分报告缺乏精确性,需要新的高质量低偏倚随机对照试验。

核心结论

  • 静脉活性药物在改善静脉症状、减轻水肿和加速静脉性溃疡愈合方面至少有中等质量证据。
  • 两项较高质量的试点随机对照试验提示地奥司明和MPFF作为利伐沙班辅助治疗可降低血栓后综合征发生率并改善深静脉再通。
  • 由于多数随机对照试验发表于二十多年前且部分缺乏报告精确性,需要新的高质量、低偏倚随机对照试验评估特定静脉活性药物预防和治疗血栓后综合征的作用。

研究设计与样本

  • 系统综述检索1980年1月1日至2023年7月14日PubMed、MEDLINE、生命科学期刊和Cochrane图书馆文献。
  • 仅纳入以英文发表的随机对照试验,采用PRISMA指南和修订版Cochrane随机对照试验偏倚风险评估工具。
  • 共识别94篇参考文献,11项随机对照试验符合纳入标准。
  • 给药的静脉活性药物为地奥司明、地奥司明/芦丁苷、微粒化纯化黄酮类组分(MPFF)和舒洛地特。
  • 纳入研究中血栓后综合征患者比例差异很大(8.6%-100%)。

主要发现

  • 两项研究提示地奥司明和MPFF作为利伐沙班辅助治疗预防血栓后综合征有益,偏倚风险低或不清楚。
  • 评估血栓后慢性静脉功能不全治疗的随机对照试验中,81.6%至85.7%为低或不清楚偏倚风险。
  • 所有研究均提示静脉活性药物对血栓后综合征治疗有益,改善静脉症状、减轻水肿并帮助静脉性溃疡愈合。

关键数值与推荐

  • 静脉活性药物改善静脉症状、减轻水肿和加速静脉性溃疡愈合至少有中等质量证据。
  • 两项较高质量的试点随机对照试验提示地奥司明和MPFF辅助利伐沙班可降低血栓后综合征发生率并改善深静脉再通。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 多数随机对照试验发表于二十多年前。
  • 部分随机对照试验缺乏报告所需的精确性。
  • 一些较老的研究省略了方法学细节。
  • 需要新的高质量、低偏倚随机对照试验评估特定静脉活性药物预防和治疗血栓后综合征的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-thrombotic syndrome (PTS) has been highly prevalent; over 50% of the patients develop PTS after lower extremity acute deep vein thrombosis. Venoactive compounds (VACs) have been recommended for decades for patients with chronic venous insufficiency, including PTS. The objective of our study was to perform a systematic review to determine the quality of evidence on the utility of VACs for both prevention and treatment of PTS. METHODS: A systematic review was conducted to search the literature between January 1, 1980, and July 14, 2023, for venoactive drugs or medications, deep vein thrombosis, and PTS using PubMed, MEDLINE, life science journals, and the Cochrane Library. Only randomized controlled trials (RCTs) published in English were included in this review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the revised Cochrane risk-of-bias tool for RCTs were used. RESULTS: Ninety-four references were identified; 11 RCTs fulfilled the inclusion criteria. VACs administered were diosmin, hidrosmin/rutosides, micronized purified flavonoid fraction (MPFF), and sulodexide. The studies included a highly variable proportion of patients with PTS (8.6%-100%). Some older studies omitted details of the methodology. Two studies suggested benefit of diosmin and MPFF as adjunctive treatment to rivaroxaban in the prevention of PTS and showed low or unclear risk of bias. Evaluation of RCTs for the treatment of post-thrombotic chronic venous insufficiency found low or unclear risk of bias in 81.6% to 85.7%. All studies suggested that VACs were beneficial for PTS treatment; they improved venous symptoms, decreased edema, and helped heal venous ulcers. CONCLUSIONS: This systematic review found that VACs had at least moderate quality of evidence in improving venous symptoms, decreasing edema, and accelerating venous ulcer healing. Two pilot RCTs of higher quality suggested the usefulness of diosmin and MPFF as adjunctive treatment to rivaroxaban therapy to reduce the incidence of PTS and improve deep vein recanalization. Because most RCTs were published over two decades ago, and several lacked the required precision in reporting, new high-quality, low-bias RCTs are needed to assess the role of specific VACs for both prevention and treatment of PTS.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Gloviczki ML, Stoughton J, Puggioni A, et al. Utility of venoactive compounds in post-thrombotic syndrome: A systematic review. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 40101859. doi:10.1016/j.jvsv.2025.102228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。